Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk

Sci Rep. 2020 Jul 10;10(1):11433. doi: 10.1038/s41598-020-68375-7.

Abstract

Venous thromboembolism is associated with formation of denser fibrin clots resistant to lysis. We investigated whether prothrombotic plasma clot properties are associated with the severity of acute pulmonary embolism (PE). We enrolled 126 normotensive acute PE patients (aged 58 ± 14 years) and 25 age- and sex-matched healthy controls. Plasma fibrin clot permeability (Ks), clot lysis time (CLT), endogenous thrombin potential (ETP), plasminogen activator inhibitor-1 (PAI-1), and citrullinated histone H3 (citH3) were evaluated on admission. PE patients compared to controls had 370% higher citH3 levels, 41% higher ETP, 16.5% reduced Ks, and 25.6% prolonged CLT. Patients with intermediate-high (n = 29) and intermediate-low (n = 77) PE mortality risk had reduced Ks and prolonged CLT, increased PAI-1 and ETP as compared to low-risk PE (n = 20) patients. Prolonged CLT was predicted by PAI-1 and citH3, while low Ks by C-reactive protein. During a 12-month follow-up 9 (7.1%) patients who had 24% higher ETP, 45% higher citH3 levels, and 18% prolonged CLT at baseline died. High ETP combined with elevated citH3 levels and prolonged CLT was associated with eightfold increased risk of PE-related death. Prothrombotic fibrin clot properties and enhanced neutrophil extracellular traps formation are associated with higher early mortality risk in acute PE patients, which suggests a prognostic role of these biomarkers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers
  • Blood Coagulation Tests
  • Case-Control Studies
  • Extracellular Traps*
  • Female
  • Fibrin / chemistry
  • Fibrin Clot Lysis Time
  • Fibrinolysis
  • Follow-Up Studies
  • Histones / blood
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood
  • Prognosis
  • Pulmonary Embolism / blood*
  • Pulmonary Embolism / mortality
  • Risk
  • Sensitivity and Specificity
  • Thrombin / metabolism
  • Thrombosis / blood*
  • Venous Thromboembolism / blood
  • Venous Thromboembolism / mortality

Substances

  • Biomarkers
  • Histones
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human
  • Fibrin
  • Thrombin